🔎 LITERATURE REVIEW
Here is a comprehensive review on MM: https://lnkd.in/danyHAYD
🧪 TRANSLATIONAL RESEARCH
“Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy” : https://lnkd.in/dbsek8aM
- The study addresses whether T-cell exhaustion is a common feature in newly diagnosed multiple myeloma patients, potentially explaining the immune evasion of cancer cells.
- However, through extensive single-cell multiomic and functional profiling, the authors found no evidence of T-cell exhaustion.
- The lack of exhausted T cells could partially explain why anti-PD-1 therapies—which aim to reinvigorate exhausted T cells—have been largely unsuccessful in MM.
“Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation” : https://lnkd.in/d-7bxA63
- Anti-BCMA CAR-T cells were engineered to release a granzyme B–NOXA fusion protein, enabling them to overcome apoptosis resistance in myeloma cells.
- The targeted delivery of MCL-1 inhibitory molecules has the potential to be applied to a broader range of cancers characterised by apoptosis resistance.
💊 CLINICAL TRIALS
“Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma” : https://lnkd.in/dk6Cwkm5
- The authors evaluated the impact of clonal hematopoiesis of indeterminate potential (CHIP) on the efficacy and safety of BCMA CAR-T therapy in MM patients. This was motivated by preclinical studies suggesting that CHIP can modulate immune cell interactions.
- Interestingly, the authors found that CHIP was not associated with therapy response or survival outcomes.
- However, CHIP was linked to delayed hematopoietic recovery after therapy—a condition that can predispose MM patients to severe infections, a frequent cause of death following CAR-T therapy.
